Contenido principal
Ir al contenido principal
Menú de navegación
No hay
Navegación secundaria
disponible para el sitio actual.
Selector de idioma
Es
En
Español
English
Cerrar
Nuestros investigadores
Menú de navegación
No hay
Navegación secundaria
disponible para el sitio actual.
Menú de navegación
No hay
Navegación secundaria
disponible para el sitio actual.
Nuestros investigadores
Cerrar
Ruta de navegación
Estás en:
Investigacion
Nuestros investigadores
Publicaciones de nuestros investigadores
Publicaciones de nuestros investigadores - Investigacion
Detalle Publicación
Plasma Aß42/40 ratio detects early stages of Alzheimer's disease and correlates with CSF and neuroimaging biomarkers in the AB255 study
Autores:
Perez-Grijalba, V.; Romero, J. ; Pesini, P. (Autor de correspondencia); Sarasa, L.; Monleon, I.; San-Jose, I. ;
Arbizu Lostao, Javier
; Martinez-Lage, P. ; Munuera, J.; Ruiz, A.; Tarraga, L.; Boada, M.; Sarasa, M.; The AB255 Study Group
Título de la revista:
JPAD
ISSN:
2274-5807
Volumen:
6
Número:
1
Páginas:
34 - 41
Fecha de publicación:
2019
Resumen:
BACKGROUND: Easily accessible biomarkers are needed for the early identification of individuals at risk of developing Alzheimer's disease (AD) in large population screening strategies. OBJECTIVES: This study evaluated the potential of plasma beta-amyloid (A beta) biomarkers in identifying early stages of AD and predicting cognitive decline over the following two years. DESIGN: Total plasma A beta 42/40 ratio (TP42/40) was determined in 83 cognitively normal individuals (CN) and 145 subjects with amnestic mild cognitive impairment (a-MCI) stratified by an FDG-PET AD-risk pattern. RESULTS: Significant lower TP42/40 ratio was found in a-MCI patients compared to CN. Moreover, a-MCIs with a high-risk FDG-PET pattern for AD showed even lower plasma ratio levels. Low TP42/40 at baseline increased the risk of progression to dementia by 70%. Furthermore, TP42/40 was inversely associated with neocortical amyloid deposition (measured with PiB-PET) and was concordant with the AD biomarker profile in cerebrospinal fluid (CSF). CONCLUSIONS: TP42/40 demonstrated value in the identification of individuals suffering a-MCI, in the prediction of progression to dementia, and in the detection of underlying AD pathology revealed by FDG-PET, Amyloid-PET and CSF biomarkers, being, thus, consistently associated with all the well-established indicators of AD.
DOI:
https://doi.org/10.14283/jpad.2018.41
Impacto:
45 citas en
Google Scholar
Oculto